Clearbridge Health also set to launch Precipio's Pathology Services and SmartPath™ Second Opinion Service
NEW HAVEN, CT / ACCESSWIRE / October 31, 2017 / Precipio, Inc. (NASDAQ: PRPO), announced today that Clearbridge Health, Pte.
Ltd. (CBH), a Singapore-based healthcare company, intends to launch Precipio's RUO ICE COLD-PCR™ (ICP) Liquid Biopsy technology.
CBH has placed an initial order of ICP kits to be delivered during Q4 of 2017 and Q1 2018. The Company also announced that CBH
intends to launch Precipio's Pathology services, as well as its SmartPath™ Second Opinion service. SmartPath™ connects the patient
and their treating physician with experts within Precipio's academic network to ensure accurate diagnoses. Precipio recently
conducted comprehensive training at CBH headquarters in Singapore with the CBH sales team representatives covering Singapore,
China, Hong Kong, India, Philippines, Malaysia and Indonesia.
"We are very excited about ICE COLD-PCR™ technology and Smartpath™," said Jeremy Yee, CEO of Clearbridge Health. "By working
with Precipio, CBH can develop and offer an advanced, cost effective liquid biopsy solution throughout its network in Asia. This
enables us to provide precision genomic profiling, which we believe supplies better information to the referring physician, leading
to more effective treatment selection and ultimately results in better outcomes for patients with cancer, and other serious
diseases."
CBH will begin the rollout of ICP and other services in Asia, where it has an established presence. Among its plans are to
expand the installation of ICP in several Asian markets.
"Now that we have launched our first ICP kit, our goal is to rapidly increase the adoption of our ICE COLD-PCR™ (ICP) technology
globally, and we believe that CBH is the ideal partner to help deliver ICP to the Asian markets," said Ilan Danieli, President and
Chief Executive Officer of Precipio. "We are pleased to receive our first ICP kit order from Clearbridge Health; and to working
with the CBH team to deliver improved, more accurate diagnoses to patients throughout Asia. We are also thrilled to commence
offering our expert second opinion and pathology capabilities, as we drive value to clients receiving access to the highest quality
healthcare services and gaining improved patient outcomes," Mr. Danieli added. "Clearbridge Health represents the first of many
customers who see the value in Precipio's combined offering of technology (ICP) and services to meet their customer's clinical
needs. This is the translation of the theoretical "synergies" that were envisioned in this merger, into practical, real customers
and business growth."
About Clearbridge Health
CBH is a company with a focus on the delivery of precision medicine in Asia. CBH's business comprises laboratory testing
services, medical clinics/centers and strategic equity participation in complementary precision medical technology companies.
Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more
reliable and accurate diagnosis, provide insights to disease management, and tailor personalized prevention and timely treatment
programmed for patients. For more information, please visit us at www.clearbridgehealth.com.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and
technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients
worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and
treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level
of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements," within the meaning of federal securities laws,
including statements related to Precipio's merger with Transgenomic, consolidation of laboratory operations, reductions of accounts
payable, plans and prospects and other statements containing the words "anticipate," "intend," "may," "plan," "predict," "will,"
"would," "could," "should," and similar expressions, constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described
in the Company's definitive proxy statement filed on May 12, 2017, the Company's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017, the Company's prior filings and from time to time in the Company's subsequent filings with the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events, and performance to
differ materially from those referred to in such statements. All information in this press release is as of the date of the release
and the Company does not undertake any duty to update this information, including any forward-looking statements unless required by
law.
Contacts:
Precipio Investor Relations:
John Marco Managing Director Core IR 377 Oak Street Garden City, NY 11530 516 222 2560 johnm@coreir.com www.coreir.com
SOURCE: Precipio, Inc.
